| アブストラクト | The incorporation of personalized medicine interventions into routine healthcare constitutes an opportunity to improve patients' quality of life, as it empowers implementation of innovative, individualized clinical interventions that maximize efficacy and/or minimize the risk of adverse drug reactions. In order to ensure equal access to genomic testing for all patients, the costs associated with these interventions must be reimbursed by payers and insurance bodies. As such, it is of utmost importance to thoroughly evaluate these interventions both in terms of their clinical effectiveness and their economic cost. This article discusses the impact of personalized medicine interventions in terms of both health outcomes and value, which directly impacts on their pricing and reimbursement by the various national healthcare systems. |
|---|
| 組織名 | The Golden Helix Foundation, London, WC2N 5AP, UK.;GeneYouIn Inc., Toronto, ON, M5B 2L7, Canada.;American Society of Pharmacovigilance, Houston, TX 77225-0433, USA.;University of Patras School of Health Sciences, Department of Pharmacy, Patras,;26504, Greece.;United Arab Emirates University, College of Medicine & Health Sciences,;Department of Pathology, Al-Ain, UAE.;United Arab Emirates University, Zayed Center of Health Sciences, Al-Ain, UAE. |
|---|
